'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results — Check Target Price

Glenmark Pharma reported a lower-than-expected performance in Q1 FY26, as revenue/Ebitda/PAT came in 9%/14%/15% below our estimates. The miss was attributed to lower business in the domestic formulation, EU and ROW segments. Moreover, higher opex dented margins.